Overview
Developing Optimal Strategies for Reducing Morbidity in Patients with Non-Cystic Fibrosis Bronchiectasis
Virtual MMR (morbidity and mortality review)
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
This case-based morbidity and mortality review (MMR) assesses the negative implications of suboptimal therapeutic management for patients with non-cystic fibrosis bronchiectasis. Cases and expert discussion focus on ensuring a prompt and accurate diagnosis of bronchiectasis, understanding the benefits of high frequency chest wall oscillation (HFCWO), and identifying patients who can benefit from HFCWO.
This activity is intended for pulmonologists, pulmonology advanced practice providers, respiratory therapists, hospitalists, internists, primary care physicians, and other clinicians who care for patients with bronchiectasis
Growing numbers of individuals are receiving a diagnosis of non-cystic fibrosis bronchiectasis, a heterogeneous pulmonary disease associated with severe respiratory infections, immunodeficiencies, or. Patients commonly experience chronic cough and sputum production, along with progressive declines in clinical and functional status. Although awareness of the condition has increased, treatment options remain limited. High frequency chest wall oscillation (HFCWO) is an airway clearance technique with efficacy in improving outcomes for patients with cystic fibrosis, but its use in non-cystic fibrosis bronchiectasis has been limited. Small-scale studies have elucidated the potential of HFCWO in reducing hospitalizations and slowing the rate of decline of lung function in patients with non-cystic fibrosis bronchiectasis. Clinicians require understanding of available HFCWO devices and data to ensure that eligible patients with non-cystic fibrosis bronchiectasis can benefit from this treatment.
Upon completion of this activity, learners will be able to:
- Describe the clinical and economic burden of non-cystic fibrosis bronchiectasis
- Compare benefits and drawbacks of various therapies for impaired airway clearance
- Identify patients who would be candidates for high frequency chest wall oscillation (HFCWO) as part of an airway clearance therapy (ACT) treatment regimen
Provided by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Electromed, Inc.
Ashwin Basavaraj, MD, FCCP, ATSF
Associate Professor of Medicine
Section Chief, Pulmonary, Critical Care & Sleep Medicine
Bellevue Hospital Center
Associate Director, Bronchiectasis and NTM program
NYU Grossman School of Medicine
New York, NY
Associate Professor of Medicine
Section Chief, Pulmonary, Critical Care & Sleep Medicine
Bellevue Hospital Center
Associate Director, Bronchiectasis and NTM program
NYU Grossman School of Medicine
New York, NY
Colin Swenson, MD
Associate Professor & Senior Physician
Director of Non-CF Bronchiectasis and NTM Lung Disease Program
Division of Pulmonary, Allergy and Critical Care Medicine
Emory University School of Medicine
Section Chief, Pulmonary & Critical Care
Medical Director, Respiratory Services
Emory St. Joseph’s Hospital
Atlanta, GA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Ashwin Basavaraj, MD, FCCP, ATSF
Consulting Agreements: Baxter, Insmed, Zambon
Advisory Board: Baxter, Dymedso, Insmed, Physio-Assist
Independent Contractor: Baxter
The following financial relationships have been provided:
Colin Swenson, MD
Speakers' Bureau: Insmed
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of any ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 45 minutes to complete. To receive credit, learners are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.
